KAĞA ELİF

Dr. KAĞA ELİF

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in Macromolecular Materials and Engineering
Verified
Journal Article
Open access
KEKAĞA ELİF
KAĞA ELİF
SKSadik KAGA
Sadik KAGA
In the study, a new strategy is presented to make PLGA (poly lactic‐co‐glycolic acid) and POEGMEMA (poly(oligo(ethylene glycol) methyl ether methacrylate)) based biodegradable and biocompatible tissue scaffold via a new physical cross‐linking method. The advantage of brushed structure of POEGMEMA polymer and the hydrophobic character of PLGA polymer is taken to make physically entangled network in aqueous media. The hydrophobic nature of PLGA allows to get scaffolds even at low ratio of PLGA (25%, w/w) when using POEGMEMA (yield: 86%). This strategy gives robust polymeric networks in aqueous media without using chemical reactions through high hydrophilic polymer content. Scaffolds with high POEGMEMA ratio (75%, w/w) show two times higher water uptake ratio (≈300%) and two times lower compression strength (19 kPa) compared to the ones with lower POEGMEMA content (50%, w/w). They also show desired degradation profiles in various aqueous solutions. While the scaffolds prepared with 25% and 50% PLGA are almost stable in first 20 days, they completely degrade in 40–50 days. Both scaffold formulations (25% PLGA‐75% POEGMEMA and 50% PLGA‐50% POEGMEMA) have similar proliferative properties for fibroblast cells. The scaffolds also do not show toxicity compared to control group according to live‐dead assay.

30 January 2025 in Macromolecular Bioscience
Verified
Journal Article
Open access
KEKAĞA ELİF
KAĞA ELİF
SKSadik Kaga
Sadik Kaga
KAKorhan Altunbas
Korhan Altunbas
NONurullah Okumus
Nurullah Okumus
Chemotherapy is generally given by intravenous (IV) administration which provides higher bioavailability than other systemic routes. However, in the case of lung cancer, the pulmonary (INH) route is the other choice for inhalable formulations. In the study, biochemical and histological parameters of Cabazitaxel (CBZ) free (2 mg kg−1) and nanoparticle (NP) (2 mg kg−1 CBZ equivalent) formulations are investigated after IV and INH administration in rats. The nanoformulation of CBZ is obtained using PEGylated polystyrene (PEG‐PST) nanoparticles obtained by PISA. While a nose and head‐only device is used for INH administration, a jugular vein is used as the IV route. Blood samples (blank, 24 h, and 48 h) are collected via carotid artery cannulas without handling in metabolism cages. According to biochemical parameters, free CBZ formulation applied via IV or INH route shows higher systemic toxicity. On the other hand, the nanoformulation of CBZ showed no signs of toxicity in both IV or INH routes. Higher and longer retention is observed in the case of inhaled nanoformulation. Histological analysis showed higher alveolar macrophage migration for inhaled nanoformulation due to enhanced retention. Results showed that nanotechnology and the lung defense system gave the advantage to end up with an inhalable nanomedicine formulation for lung cancer.

1 December 2024 in Cancer Management and Research
Verified
Journal Article
Open access
MDMustafa Duran
Mustafa Duran
KEKAĞA ELİF
KAĞA ELİF
Objective: Myeloid leukemia is a stem cell disease with high mortality due to the challenges of high-dose treatments and side effects. Innovative nanoparticle drug delivery systems are being explored to enhance efficacy and tissue-targeted therapy. This study investigates the potential of Bentonite (BNT)-based nanoparticles (NPs) as drug carriers for azacitidine (AZA) in treating THP-1 and K562 myeloid leukemia (AML) cell lines, aiming to improve drug stability, bioavailability, and therapeutic efficacy while ensuring controlled release. Material and Method: Bentonite clay morphology was analyzed using Scanning Electron Microscopes. The BNT-AZA combination was tested in THP-1 and K562 cell cultures via in vitro proliferation tests, CCK-8 assays, and drug release tests with dialysis membranes. Apoptosis and internalization were evaluated using Annexin V-FITC and fluorescence methods, respectively. Results: The BNT-AZA exhibited controlled release over 8 hours, with 50% released within 2 hours, 90% by the 4th hour, and prolonged release beyond 8 hours. This profile reduces side effects while increasing efficacy in target cells. Bentonite demonstrated significant drug-loading capacity, controlled release, and tumor-targeting capabilities. At concentrations of 10, 25, 50, and 100 mu g/mL, BNT showed dose-dependent antiproliferative effects, maintaining low cytotoxicity at lower concentrations. The combination of azacytidine and bentonite exhibited a synergistic effect in inhibiting cell proliferation, with significant decreases in cell viability in the 1 mu M azacytidine + 10 mu g/mL bentonite, 5 mu M azacytidine + 10 mu g/mL bentonite, and 10 mu M azacytidine + 10 mu g/mL bentonite groups compared to the controls. The combination of 1 mu M AZA with 10 mu g/mL BNT achieved similar efficacy to 10 mu M AZA alone, suggesting a potential for dose reduction and improved safety. Conclusion: BNT nanoparticles are promising carriers for AZA, enhancing targeted delivery, reducing side effects, and potentially lowering the required dose for leukemia treatment. These findings support further investigation into the clinical application of BNTAZA in hematologic cancers.

11 November 2024 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
CICaglar Tuna Issi
Caglar Tuna Issi
BYBİLGE KAĞAN YILMAZ
BİLGE KAĞAN YILMAZ
SKSadik KAGA
Sadik KAGA
HDHasan Huseyin Demirel
Hasan Huseyin Demirel
KEKAĞA ELİF
KAĞA ELİF
MKMehmet Nuri Konya
Mehmet Nuri Konya
Biomaterials used in fracture healing hold a significant place in orthopedics. This study aimed to develop biomaterials coated with hydroxyapatite (HA), boric acid (BA), and magnesium (Mg) and investigate their effects on fracture healing. Sixty female Wistar Albino rats were included in the study. The subjects were randomized into five groups. Cytotoxicity tests were performed on HA, BA, and Mg, and cell viability rates were calculated. Coatings were applied to Kirschner (K) wires at determined ratios. Group I was the control group with a steel K wire, Group II used HA-coated K wires, Group III used HA + BA-coated K wires, Group IV used HA + BA + Mg-coated K wires, and Group V used HA + Mg-coated K wires. A fracture was induced in the right femur of the subjects, followed by fixation with intramedullary K wires. The subjects were randomly divided into equal numbers and sacrificed at 6 and 12 weeks. Radiological and histopathological evaluations were performed. In direct cytotoxicity tests, the highest viability rate was observed in Group IV, while in indirect cytotoxicity tests, it was highest in Group II. In radiological evaluation at the 6th week, the highest scores were in Groups IV and V, while the lowest was in Group III. At the 12th week, the highest scores were in Groups II and V, while the lowest was in Group I. No significant differences were found between the groups (p = 0.837, p = 0.0479). In histopathological evaluation, a significant difference was observed between the groups (p < 0.001), with the highest scores in Group V. A correlation was found between the radiological and histopathological scores (p < 0.001, r = 0.438). It was found that HA + Mg significantly improved histological outcomes in fracture healing. Good histological results can be achieved with the use of Mg-containing implants in both early and late-stage fracture healing. Coating the biomaterials used in fracture fixation with Mg may lead to positive outcomes in fracture healing.

7 August 2025 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
BYBİLGE KAĞAN YILMAZ
BİLGE KAĞAN YILMAZ
SKSadik KAGA
Sadik KAGA
KEKAĞA ELİF
KAĞA ELİF
HDHasan Huseyin Demirel
Hasan Huseyin Demirel
MKMehmet Nuri Konya
Mehmet Nuri Konya
Osteochondral defect (OCD) regeneration is difficult due to the different properties and repair potentials of bone and cartilage tissues. This study aimed to compare cartilage tissue healing by applying in vitro produced double-layered and single-layered scaffolds to osteochondral defects. Ninety male Wester Albino rats with an age of over twelve weeks and a weight of 300–350 g were included in study. Group A was the control group (isolated OCD), Group B received a cellular double-layered scaffold, Group C received a cell-free double-layered scaffold, Group D received a cellular single-layered scaffold, and Group E received a cell-free single-layered scaffold. Biodegradable double-layered and single-layered scaffolds were obtained using L-lactide-co-glycolide (PLGA) and hydroxyapatite (HA) in the bone layer, PLGA and polyethylene glycol methyl ether methacrylate (PEGMEMA) in the cartilage layer. The resulting tissues were stained with Hematoxylin-Eosin and Masson’s Tricrom. Improvement was evaluated at week 4, week 8, and week 12 according to the Modified Mankin and O’Driscol scales. The positive impact of scaffold-based cellular applications on morphological field changes was demonstrated. Groups B and C exhibited higher morphological field scores compared to groups D and E. In both scoring systems, group E showed a significant long-term increase. Although the vitality of chondrocyte cells in the scaffolds was confirmed, their desired effects diminished over time. The lowest cell population scores were observed in groups B and D. Although chondrocyte cells demonstrated sustained viability in the double-layered scaffold during the early period, this effect was not observed in the mid and late periods. The double-layered scaffold had a limited effect in enhancing osteochondral regeneration. The single-layered scaffold was more effective in enhancing regeneration in the late period. Given the favorable late period outcomes associated with the single-layered scaffold, we propose that further clinical and laboratory studies focus on its long-term results.

12 September 2025 in Engineering in Life Sciences
Verified
Journal Article
Open access
KEKAĞA ELİF
KAĞA ELİF
SKSadik Kaga
Sadik Kaga
OYOzlem Yalcin
Ozlem Yalcin
GEGizem Fatma Erguner
Gizem Fatma Erguner
NONurullah Okumus
Nurullah Okumus
Circulating tumor cells (CTCs) are cancer cells present in the bloodstream that originate from primary or metastatic sites. Sensitive and selective capture of these rare cells is essential for early diagnosis, metastasis prevention, and prognosis prediction. In this study, we demonstrated the effectiveness of a surface functionalized with epithelial cell adhesion molecule (EpCAM) Fab’ (fragment‐antigen‐binding) fragments for the specific capture of EpCAM‐positive human breast cancer cells. EpCAM antibody Fab’ fragments were produced through pepsin digestion and characterized by SDS‐PAGE analysis. Glass surfaces were silanized before being coated with a thin layer of gold via sputtering to ensure stability. The Fab’ fragments were immobilized on the gold‐coated glass surfaces through strong gold‐thiol bonds. The modified surfaces were then characterized using Fourier‐transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and atomic force microscopy (AFM) analyses. Cell capture performance was assessed using fluorescence microscopy with both EpCAM‐positive and EpCAM‐negative cell lines. The results show that the Fab’‐modified surface offers a promising platform for the selective immunocapture of EpCAM‐positive cells.Practical application: This study presents a preliminary design of a Fab’ fragment‐immobilized surface for the selective capture of EpCAM‐positive breast cancer cells. The surface modification relies on spontaneous Au‐S bonding, offering a simple and effective chemical method. The modified surface demonstrates strong potential for integration into future biosensor platforms for detecting circulating tumor cells. Such a system is promising for advanced diagnostics, monitoring, disease progression, and personalized treatment uses.